|Headquarters||Horsham, Pennsylvania, |
|Michael Yang (Immunology President)|
|Products||golimumab IV (Simponi Aria), infliximab (Remicade), golimumab (Simponi), ustekinumab (Stelara)|
|Parent||Johnson & Johnson|
Janssen Biotech, Inc., formerly Centocor Biotech, Inc., is a biotechnology company that was founded in Philadelphia in 1979 with an initial goal of developing new diagnostic assays using monoclonal antibody technology.
In 1982 Centocor transitioned into a publicly traded company. Subsequently, the company moved to a larger facility in Malvern, Pennsylvania (a northwest suburb of Philadelphia). In 1984, Centocor opened an overseas plant in Leiden, the Netherlands.
In 1999, Centocor became a wholly owned subsidiary of Johnson & Johnson, the worldwide manufacturer and marketer of healthcare products. Since being acquired by Johnson and Johnson, Centocor has increased its annual sales from approximately $500 million to more than $2 billion. During the same period, research and development investment increased from $75 million to more than $300 million.
In 2004 Centocor purchased a new manufacturing plant in St. Louis, Missouri, and is currently opening a new manufacturing facility in County Cork, Ireland. The Dutch plant has been expanded substantially with a $250 million investment in additional production facilities, which were opened in 2006.
In 2007, Centocor broke new ground in advertising by releasing Innerstate, believed to be the first theatrically released documentary film both created and entirely funded by a drug company, to promote Remicade (Infliximab).
In 2008, Centocor, Inc. and Ortho Biotech Inc. merged to form Centocor Ortho Biotech Inc.
In June 2011 Centocor Ortho Biotech changed its name to Janssen Biotech, Inc. as part of a global effort to unite the Janssen Pharmaceutical Companies around the world under a common identity.
In December 2014, the company announced it would co-develop MacroGenics cancer drug candidate (MGD011) which targets both CD19 and CD3 proteins in treating B-cell malignant tumours. This could net MacroGenics up to $700 million.
In January 2015, the company announced it will utilise Ionis Pharmaceuticals' (formerly Isis Pharmaceuticals) Rna-targeting technology to discover and develop antisense drugs targeting autoimmune disorders of the gastrointestinal tract, with the partnership potentially generating up to $835 million for Ionis.
In 1998 the company launched its top-selling monoclonal antibody Remicade (infliximab) for its first FDA approved indication in Crohn's disease. Subsequently, Remicade's market has expanded with approvals for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and pediatric Crohn's disease. Remicade was approved for plaque psoriasis in September 2006.
- Centocor reaches agreement to sell oncology diagnostics business, 1998 press release
- Stephanie Saul. "Drug Gets a Cameo in a Film Backed by Its Maker", New York Times, February 21, 2007. https://www.nytimes.com/2007/02/21/business/media/21adco.html
- Centocor Ortho Biotech Acquires RespiVert Archived 2010-06-05 at the Wayback Machine News article from InfoGrok.
- George, John. "Remicade maker Centocor Ortho Biotech changing name". Philadelphia Business Journal. Retrieved 15 January 2019.
- "Janssen Joins MacroGenics in Up-to-$700M Cancer Collaboration - GEN". GEN.
- "Janssen, Isis Pharma Ink Up-to-$835M Antisense Agreement - GEN". GEN.
- Marcial, Gene (4 May 2009). "Marcial: Medarex, a Bright Spot in Biotech". businessweek.com. Retrieved 24 Sep 2014.